Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | Unknown | IM / LA |
the nurse inadvertently gave Rabavert as an infiltration around the wound; Case reference number US-BN-2025-001429 is a spontaneous case initially received from a pharmacist via agency (reference number: USBAV25-2082) on 20-Aug-2025 and concerns a 25-year-old male patient. The patient's medical history and concomitant medication details were not provided. On *15-Aug-2025*, the patient experienced exposure to animal. On *the same day*, the patient received the first RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection, and needle for reconstitution (batch number: unknown) at an unknown dose, *via infiltration and intramuscularly to the finger and left deltoid*, for post-exposure prophylaxis. On 18-Aug-2025, *three days after the exposure to animal and after the first dose*, the patient received the second RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection, and needle for reconstitution (batch number: unknown) at an unknown dose, *intramuscularly in the right arm*, for post-exposure prophylaxis. As reported, an infiltration around the wound like would immunoglobulin (explicitly coded as 'vaccine administered at inappropriate site'). *On 22-Aug-2025, seven days after the exposure to animal and after the first dose, the patient received the third RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection, and needle for reconstitution (batch number: unknown) at dose of 1 mL, intramuscularly to an unknown site of administration.* *On 29-Aug-2025, 14 days after exposure to the animal and after the first dose, the patient received the fourth RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection, and needle for reconstitution (batch number: unknown) at dose of 1 mL, intramuscularly to an unknown site of administration. * *At the time of the follow-up report, the patient did not experience any adverse events due to RabAvert.* All updated information is blended into the case narrative above, with the latest information presented between asterisks (*). Follow-up information was received from a pharmacist on 10-Sep-2025: New information included patient initials, date of animal exposure, RabAvert dosing regimen details (routes and sites of administration, dates, dose), and confirmation that the patient did not experience adverse events due to RabAvert.; Reporter's Comments: A 25-year-old male patient received the first dose of RabAvert vaccine for post-exposure prophylaxis. As reported, the patient received the second dose of RabAvert, as an infiltration around the wound like would immunoglobulin, which is considered as product administered at inappropriate site. Product administered at inappropriate site is considered as listed per company convention. The patient did not experience any adverse events due to RabAvert. The patient's relevant medical history and concomitant medication details were not provided. Product administered at inappropriate site is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 25-year-old male patient received the first dose of RabAvert vaccine for post-exposure prophylaxis. As reported, the patient received the second dose of RabAvert, as an infiltration around the wound like would immunoglobulin, which is considered as product administered at inappropriate site. Product administered at inappropriate site is considered as listed per company convention. The patient did not experience any adverse events due to RabAvert. The patient's relevant medical history and concomitant medication details were not provided. Product administered at inappropriate site is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.